explore -WSS

explore

author：explore 2025-08-24 23:06:39 - browse：3855

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： A pediatrician calls for Congress to pass the child tax credit deal

entertainment

WSS

Printout prescription drug information shouldn’t go digital

Pumping milk in bathrooms at health conferences is common

How digital therapeutics firms are pivoting after Pear's bankruptcy

Inaction leaves children at risk from dangerous chemotherapy drug

The surgeon had a dilemma only a Nazi medical text could resolve

Medicare drug price lawsuits could be good politics for Biden

explore

explore

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Merck, J&J, and long Covid

Virginia high school admissions case could be legal follow

New brain studies show LSD's effects on the brain in full color

Anesthesiologist group: stop taking Ozempic before surgery

eGenesis tests gene

Walensky prepares to leave CDC — and Congress — behind

How digital therapeutics firms are pivoting after Pear's bankruptcy

Continuity nursing helped my family in our darkest PICU moments

Head of FDA's diagnostics center, who led through Covid, retires

Wikipedia

Dog Aging Project founders on what lies ahead after losing funding

Elizabeth Holmes banned from government health programs

Update the Apgar Score to remove skin color

Why doctors need education on FDA device approval process

Inaction leaves children at risk from dangerous chemotherapy drug

Dewpoint Therapeutics lays off staff after losing partnerships

explore

entertainment

hotspot

entertainment